Bioperfectus Technologies (688399.SH) announced that it has recently received medical device registration certificates (in vitro diagnostic reagents) issued by the National Medical Products Administration.

The products covered are the Hepatitis C Virus Nucleic Acid Detection Kit (Fluorescence PCR Method) and the Chikungunya Virus Nucleic Acid Detection Kit (Fluorescence PCR Method).

The acquisition of these Medical Device Registration Certificates has enriched the company's product portfolio and expanded its presence in the in vitro diagnostics sector, continuously meeting diverse clinical needs, enhancing the company's overall competitiveness, and helping to further improve its market expansion capabilities.